PCC and Fibrinogen Compared With FFP in PPH
Postpartum Haemorrhage
About this trial
This is an interventional treatment trial for Postpartum Haemorrhage
Eligibility Criteria
Inclusion Criteria:
Women who have delivered vaginally or by caesarean section with a PPH of 2000 ml (the amount of blood loss: in addition to the suctioned blood, sponges, wraps, swabs, etc. are carefully weighed)
Exclusion Criteria:
Women with a history of bleeding tendency or hepatic or renal insufficiency, or PPH exceeding 3000 ml because in that case the initial need for fibrinogen may be even more
Sites / Locations
- Maternity Hospital, Helsinki University Central Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
PCC group
FFP group
Twenty patients in the PCC group receive 15 IU/kg of Octaplex concentrate and 2 g of Riastap concentrate. Additional fibrinogen is administered (if needed) to increase the baseline FIBTEM-MCF (at 5 min) to the target of 15 mm.
Twenty patients in the FFP group receive 4 units of FFP (Octaplas). Additional fibrinogen (Riastab) is administered (if needed) to increase the baseline FIBTEM-MCF (at 5 min) to the target of 15 mm. The fibrinogen content of the FFP will be taken into consideration (2.1 g in 4 units of FFP).